Flortaucipir F 18

Drug Profile

Flortaucipir F 18

Alternative Names: 18F-AV-1451; [18F] T 807; [F-18]T807; F-18-AV-1451; Fluorine 18 AV 1451; T807

Latest Information Update: 16 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Siemens Medical Solutions
  • Developer Avid Radiopharmaceuticals; Mayo Clinic; University of Pennsylvania
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Alzheimer's disease
  • Phase II Brain injuries; Cognition disorders; Dementia; Depressive disorders; Neurodegenerative disorders; Progressive supranuclear palsy
  • Clinical Phase Unknown Aphasia

Most Recent Events

  • 28 Jul 2017 Avid Radiopharmaceuticals completes a phase II/III trial (Diagnosis, In adults, In the elderly) for Alzheimer's disease in USA (IV) (NCT02016560)
  • 13 Jun 2017 Phase-I clinical trials in Alzheimer's disease (Diagnosis, In the elderly, In volunteers, In adults) in USA (IV) (NCT03189485)
  • 01 Apr 2017 Phase-I clinical trials in Dementia (Diagnosis, In adults, In the elderly) in USA (IV) (NCT03040713)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top